Uso de tocilizumab en artritis reumatoide en México
Latin american journal of clinical sciences and medical technology · 2020
DOI: 10.34141/ljcs1181908 ↗Kurz gefasst
Fachartikel in der Zeitschrift Latin american journal of clinical sciences and medical technology, 2020. Verfasst von Leonor Adriana Barile-Fabris und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and objective. Rheumatoid arthritis (RA) is a chronic and inflammatory disease affecting millions of people and making an enormous economic impact. The healthcare coverage for RA in Mexico is limited and the biologic drugs are conditioned to mild or severe disease, or to failure or inappropriate response to the conventional synthetic disease-modifying antirheumatic drugs (DMARDcs). The objective of this article was to determine whether if there is enough evidence supporting the efficacy of tocilizumab (TCZ) as the first-line treatment for RA, administered as monotherapy or in combination with DMARDcs. Material and Methods. A rheumatology expert group conducted a systematic review of the literature in order to analyze the efficacy and safety of TCZ as a biologic DMARD in combination with DMARDcs and as monotherapy in patients with RA. The group used the search strategy known as 6S for evidence-based medicine.
Results
A total of 44 articles were analyzed. For clinical evidence, we found randomized controlled trials (RCT) showing more significant benefit in the groups, which received TCZ alone or in combination, according to the evaluation made with clinimetric tools. These six trials had at least a 52-week follow-up (up to 260 weeks) and included 3,413 subjects. Two RCT —including 1,479 patients— identified that the most frequent adverse event was rhinopharyngitis.
Discussion
There is enough evidence to suggest that TCZ may be administered in patients with failure to biologics or as a first-line treatment, both in combination with methotrexate (MTX) (or other drugs) and in intravenous or subcutaneous monotherapy. TCZ is an effective and applicable alternative for the Mexican population in first line and in failure to DMARD, with or without MTX.
Zitieren
APA
Barile-Fabris, L. A., Sicsik-Ayala, S. A., Hernández-Cabrera, M. F., Tinajero-Nieto, L., Xibillé-Friedmann, D., Castro-Colin, Z., Carrillo-Vázquez, S., & Ramírez-Santillán, K. (2020). Uso de tocilizumab en artritis reumatoide en México. Latin american journal of clinical sciences and medical technology. https://doi.org/10.34141/ljcs1181908
Vancouver
Barile-Fabris LA, Sicsik-Ayala SA, Hernández-Cabrera MF, Tinajero-Nieto L, Xibillé-Friedmann D, Castro-Colin Z, et al. Uso de tocilizumab en artritis reumatoide en México. Latin american journal of clinical sciences and medical technology. 2020. doi:10.34141/ljcs1181908
BibTeX
@article{BarileFabris2020,
author = {Barile-Fabris, Leonor Adriana and Sicsik-Ayala, Sandra Araceli and Hernández-Cabrera, María Fernanda and Tinajero-Nieto, Lizbet and Xibillé-Friedmann, Daniel and Castro-Colin, Zully and Carrillo-Vázquez, Sandra and Ramírez-Santillán, Katia},
title = {Uso de tocilizumab en artritis reumatoide en México},
journal = {Latin american journal of clinical sciences and medical technology},
year = {2020},
doi = {10.34141/ljcs1181908}
}
EUVIMED